📢 #Pharmacogenomics (#PGx) plays a crucial role in our mission at the Institute for Precision Medicine. Under the guidance of Philip Empey, PharmD, PhD, Associate Director at IPM and Associate Professor at the University of Pittsburgh School of Pharmacy, UPMC’s system-wide clinical implementation of PGx is facilitated by the PreCISE-Rx Program. This program enhances patient care by integrating clinical decision tools into electronic health records, allowing tailored treatment based on #genetic findings. To explore how pharmacogenomics can lead to improved patient outcomes, read our updated IPM brochure [Page 12-13]: https://lnkd.in/ehqkGf5x
Sanford Health’s Post
More Relevant Posts
-
Director Continuing Pharmacy Education; Assistant Director Clinical Pharmacogenomics and Precision Medicine Graduate Program; Clinical Associate Professor: UF College of Pharmacy
Want to learn more about our Pharmacogenomics/Precision Medicine graduate programs and hear from an expert in the field? Join us tomorrow for an information webinar. Attendance is free! #CPPM #pharmacogenomics #precisionmedicine #individualizedmedicine #webinar #graduateprograms #medicationmanagement #pharmacists
To view or add a comment, sign in
-
Inviting medical providers, engineers, pharmaceutical scientists, as well as designers to explore topics on biomedical monitoring, medication storage, extreme clothing design, as well as a discussion of the science around the management of hypothermia and cold injury. Frozen feet, cold medications, inability to provide consistent monitoring, patchy communications and navigation — these are just some of the many issues faced by people in extreme cold. This interdisciplinary symposium seeks to tackle the topic of medicine at the extremes and how we might address the challenges of providing medical care in these conditions. Learn more at: https://lnkd.in/eFSp39ED
To view or add a comment, sign in
-
-
Today and yesterday presentation of the @COREMDproject final results. https://www.core-md.eu CORE-MD established an excellent consortium with stakeholders from regulators , clinicians ( EFORT @european society of cardiology Biomedical Alliance in Europe Alliance in Europe ), scientists, patients (European Patients' Forum forum) to give scientific advice on high risk medical devices. Clinical evidence, meaning Performance and Safety, is key for high risk medical devices. input from the Expert Panels under the European Society of Cardiology process as well as in giving advice to manufacturers (European Medicines Agency agency) on optimal study design in the preclinical phase. As for #Orthopaedics (EFORT informed consent and including study patients in Registries (Landelijke Registratie Orthopedische Interventies (LROI) @NJR etc ) safeguards also PMCF. https://www.core-md.eu
To view or add a comment, sign in
-
-
🚨⚠️The FDA's Final LDTs Rule Is Out—Now What?📢🔔 The FDA’s final rule on laboratory-developed tests contains some surprises. Shannon Bennett, director of regulatory affairs in the Dept. of Laboratory Medicine and Pathology at Mayo Clinic, shares his initial thoughts on the rule and what labs need to do: 👉 What will be most challenging for medical labs? 👉 What do labs need to do now to address the rule? Learn more here ⬇️⬇️ https://lnkd.in/eitXghxB #FDA #LDTs #LabDevelopedTests #MedLab
To view or add a comment, sign in
-
-
Effective solutions begin with clean and compelling data. If you *Know* you know. 😁
Today we announced the interim results from our latest clinical research study. The study assessed the accuracy of Know Labs’ proprietary radiofrequency (RF) dielectric sensor in non-invasively measuring blood glucose in participants with prediabetes and Type 2 diabetes using venous blood as reference – resulting in an overall Mean Absolute Relative Difference (MARD) of 11.1%. This is our first clinical research protocol involving participants with diabetes and venous blood as a comparative reference, and we are encouraged by the continued stability of Know Labs' novel sensor technology and algorithms. We will present the study results at the 17th International Conference at Advanced Technologies & Treatments for Diabetes (ATTD) in Florence, Italy on March 6-9, 2024. See more in our press release here: https://lnkd.in/gNhw42nd #CGM #Diabetes #ATTD2024
Know Labs’ Non-Invasive Glucose Monitor Achieves 11.1% MARD in Latest Clinical Research Study
knowlabs.co
To view or add a comment, sign in
-
Earn #FreeCME with our activity series 'Real World Retina.' This series includes four activities each with unique faculty perspectives. In 'Diabetic Macular Edema Management Challenges,' Drs. Diana Do, Mark Barakat, MD, and Jennifer Lim evaluate the evidence for anti-VEGF treatment outcomes for DME in clinical practice, identify prognostic indicators for predicting anti-VEGF therapy outcomes, and assess the latest evidence regarding safety, efficacy, and durability of new therapies for the management of DME. This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. Complete the activity using this link: https://ow.ly/3FiN50Qe7xv
To view or add a comment, sign in
-
-
You can learn more about NanoPhotometer from Implen at our booth in Medlab Series - Medical Laboratory Industry Forum. Do not miss out the opportunity to speak with the experts. #medlabmiddleeast #medlab #implen #NanoPhotometer #gba
Implen NanoPhotometer at MedLab 2024
To view or add a comment, sign in
-
🧬 #UKPGx2024 is here! 🧬 We're at the Royal College of Physicians, London, for a packed day of talks, networking and collaboration in the fields of pharmacogenetics and stratified medicine! See you all very soon! #Pharmacogenetics #Pharmacogenomics #PGx #UKPGx #StratifiedMedicines
To view or add a comment, sign in
-
Interested in learning more about AAV.SPR? Our novel capsid, which is designed to spread laterally in tissue well beyond subretinal injection bleb margins, is being utilized in the ongoing LIGHTHOUSE study evaluating our investigational #GeneTherapy ATSN-201 for X-linked retinoschisis (#XLRS). Data from IND-enabling studies supporting the clinical development of ATSN-201 were presented at the #ESGCT 30th Annual Congress. #ICYMI, check out the presentation here: https://lnkd.in/eD-TFXXD
To view or add a comment, sign in
-